The genetic fingerprint
The biology of a melanoma and the defense response within the skin differ from individual to individual. Therefore, your treatment should also be tailored to your individual needs. Once MelaGenix has provided you with knowledge of your personal relapse risk, your physician can decide whether treatment is necessary.
Histological tissue examination
New: More precise prognosis by
Even after the complete surgical removal of a melanoma, about 15% of all patients are not permanently cured. Individual tumor cells can spread, causing a relapse. This affects also patients who have been diagnosed with an early stage of cutaneous malignant melanoma.
Your genes have an impact on your disease. Therefore standard tissue examination cannot safely predict the course of your disease and your relapse risk. The MelaGenix gene expression test captures the genetic fingerprint (signature) of your melanoma and your surrounding skin tissue to precisely assess your relapse risk.
MelaGenix helps you and your physician to make the best possible decisions regarding further melanoma treatment and follow-up.